Cargando…

The European Cystic Fibrosis Society Patient Registry: valuable lessons learned on how to sustain a disease registry

BACKGROUND: Disease registries have the invaluable potential to provide an insight into the natural history of the disease under investigation, to provide useful information (e.g. through health indicators) for planning health care services and to identify suitable groups of patients for clinical tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Viviani, Laura, Zolin, Anna, Mehta, Anil, Olesen, Hanne Vebert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4066270/
https://www.ncbi.nlm.nih.gov/pubmed/24908055
http://dx.doi.org/10.1186/1750-1172-9-81
_version_ 1782322158386544640
author Viviani, Laura
Zolin, Anna
Mehta, Anil
Olesen, Hanne Vebert
author_facet Viviani, Laura
Zolin, Anna
Mehta, Anil
Olesen, Hanne Vebert
author_sort Viviani, Laura
collection PubMed
description BACKGROUND: Disease registries have the invaluable potential to provide an insight into the natural history of the disease under investigation, to provide useful information (e.g. through health indicators) for planning health care services and to identify suitable groups of patients for clinical trials enrolment. However, the establishment and maintenance of disease registries is a burdensome initiative from economical and organisational points of view and experience sharing on registries management is important to avoid waste of resources. The aim of this paper is to discuss the problems embedded in the institution and management of an international disease registry to warn against common mistakes that can derail the best of intentions: we share the experience of the European Cystic Fibrosis Society Patient Registry, which collects data on almost 30,000 patients from 23 countries. METHODS: We discuss the major problems that researchers often encounter in the creation and management of disease registries: definition of the aims the registry has to reach, definition of the criteria for patients referral to the registry, definition of the information to record, set up of a data quality process, handling of missing data, maintenance of data confidentiality, regulation of data use and dissemination of research results. RESULTS: We give examples on how many crucial aspects were solved by the European Cystic Fibrosis Society Patient Registry regarding objectives, inclusion criteria and variables definition, data management, data quality controls, missing data handling, confidentiality maintenance, data use and results dissemination. CONCLUSIONS: We suggest an extensive literature research and discussions in working groups with different stake holders, including patient representatives, on the objectives, inclusion criteria and the information to record. We propose to pilot the recording of few variables and test the applicability of their definition first. The use of a shared electronic platform for data collection that automatically computes derived variables, and automatically performs basic data quality controls is a good data management practice, that also helps in reducing missing data. We found crucial for success the collaboration with existing national and international registries, cystic fibrosis organisations and patients’ associations.
format Online
Article
Text
id pubmed-4066270
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-40662702014-06-24 The European Cystic Fibrosis Society Patient Registry: valuable lessons learned on how to sustain a disease registry Viviani, Laura Zolin, Anna Mehta, Anil Olesen, Hanne Vebert Orphanet J Rare Dis Research BACKGROUND: Disease registries have the invaluable potential to provide an insight into the natural history of the disease under investigation, to provide useful information (e.g. through health indicators) for planning health care services and to identify suitable groups of patients for clinical trials enrolment. However, the establishment and maintenance of disease registries is a burdensome initiative from economical and organisational points of view and experience sharing on registries management is important to avoid waste of resources. The aim of this paper is to discuss the problems embedded in the institution and management of an international disease registry to warn against common mistakes that can derail the best of intentions: we share the experience of the European Cystic Fibrosis Society Patient Registry, which collects data on almost 30,000 patients from 23 countries. METHODS: We discuss the major problems that researchers often encounter in the creation and management of disease registries: definition of the aims the registry has to reach, definition of the criteria for patients referral to the registry, definition of the information to record, set up of a data quality process, handling of missing data, maintenance of data confidentiality, regulation of data use and dissemination of research results. RESULTS: We give examples on how many crucial aspects were solved by the European Cystic Fibrosis Society Patient Registry regarding objectives, inclusion criteria and variables definition, data management, data quality controls, missing data handling, confidentiality maintenance, data use and results dissemination. CONCLUSIONS: We suggest an extensive literature research and discussions in working groups with different stake holders, including patient representatives, on the objectives, inclusion criteria and the information to record. We propose to pilot the recording of few variables and test the applicability of their definition first. The use of a shared electronic platform for data collection that automatically computes derived variables, and automatically performs basic data quality controls is a good data management practice, that also helps in reducing missing data. We found crucial for success the collaboration with existing national and international registries, cystic fibrosis organisations and patients’ associations. BioMed Central 2014-06-07 /pmc/articles/PMC4066270/ /pubmed/24908055 http://dx.doi.org/10.1186/1750-1172-9-81 Text en Copyright © 2014 Viviani et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Viviani, Laura
Zolin, Anna
Mehta, Anil
Olesen, Hanne Vebert
The European Cystic Fibrosis Society Patient Registry: valuable lessons learned on how to sustain a disease registry
title The European Cystic Fibrosis Society Patient Registry: valuable lessons learned on how to sustain a disease registry
title_full The European Cystic Fibrosis Society Patient Registry: valuable lessons learned on how to sustain a disease registry
title_fullStr The European Cystic Fibrosis Society Patient Registry: valuable lessons learned on how to sustain a disease registry
title_full_unstemmed The European Cystic Fibrosis Society Patient Registry: valuable lessons learned on how to sustain a disease registry
title_short The European Cystic Fibrosis Society Patient Registry: valuable lessons learned on how to sustain a disease registry
title_sort european cystic fibrosis society patient registry: valuable lessons learned on how to sustain a disease registry
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4066270/
https://www.ncbi.nlm.nih.gov/pubmed/24908055
http://dx.doi.org/10.1186/1750-1172-9-81
work_keys_str_mv AT vivianilaura theeuropeancysticfibrosissocietypatientregistryvaluablelessonslearnedonhowtosustainadiseaseregistry
AT zolinanna theeuropeancysticfibrosissocietypatientregistryvaluablelessonslearnedonhowtosustainadiseaseregistry
AT mehtaanil theeuropeancysticfibrosissocietypatientregistryvaluablelessonslearnedonhowtosustainadiseaseregistry
AT olesenhannevebert theeuropeancysticfibrosissocietypatientregistryvaluablelessonslearnedonhowtosustainadiseaseregistry
AT vivianilaura europeancysticfibrosissocietypatientregistryvaluablelessonslearnedonhowtosustainadiseaseregistry
AT zolinanna europeancysticfibrosissocietypatientregistryvaluablelessonslearnedonhowtosustainadiseaseregistry
AT mehtaanil europeancysticfibrosissocietypatientregistryvaluablelessonslearnedonhowtosustainadiseaseregistry
AT olesenhannevebert europeancysticfibrosissocietypatientregistryvaluablelessonslearnedonhowtosustainadiseaseregistry